2022 Volume 1 Issue 4 Pages 299-308
Introduction: Inflammation-based prognostic scores (IBPSs) is suggested to be associated with prognosis in many carcinomas including oral squamous cell carcinoma (OSCC), but we are skeptical that each IBPS alone is a strong prognostic factor. We examined whether IBPSs are valid prognostic predictors in a retrospective cohort study of patients undergoing primary surgery for OSCC.
Methods: The study was performed in 287 patients with OSCC primarily treated by surgery from 2007 to 2019 at our center. The IBPSs examined were the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), prognostic index (PI), and modified Glasgow prognostic score (mGPS), evaluated by blood tests at the first visit and at the end of primary treatment.
Results: There was no significant difference in OS and DFS between the two groups based on the cutoffs for NLR, PLR and LMR at first visit. Similarly, a comparison in OS and DFS for cases with mGPS and PI scores of 0 and 1 + 2 at the first visit showed no significant difference. The relative (at the end of primary treatment/the first visit) NLR, PLR and LMR had no effect on death or events. Whereas, worsening of mGPS and of PI at the end of primary treatment were both significantly correlated with poor prognosis for death and events (both p < 0.001).
Conclusions: This study found that IBPSs were not effective as presurgical prognostic factors for patient with OSCC in our center. Further investigation and validation of indices and assessment methods are required to improve the impact of IBPS biomarkers on prognosis prediction and treatment choice in patients with OSCC.
